Roivant Sciences Ltd. (ROIV) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
ROIV's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ROIV Revenue Analysis (2019–2024)
As of March 2, 2026, Roivant Sciences Ltd. (ROIV) generated trailing twelve-month (TTM) revenue of $13.3 million, reflecting significant decline in growth of -77.8% year-over-year. The most recent quarter (Q3 2025) recorded $2.0 million in revenue, up 27.2% sequentially.
Looking at the longer-term picture, ROIV's 5-year compound annual growth rate (CAGR) stands at -15.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $67.7 million in 2019.
Revenue diversification analysis shows ROIV's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), ROIV has underperformed the peer group in terms of revenue growth. Compare ROIV vs REGN →
Peer Comparison
Compare ROIV's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ROIVCurrent | $13M | -77.8% | -15.6% | -3453.3% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $29.1M | -11.2% | $28.1M | 96.9% | $-1,003,294,000 | -3453.3% |
| 2023 | $32.7M | -46.6% | $31.1M | 95.1% | $4.50B | 13746.9% |
| 2022 | $61.3M | +10.8% | $48.2M | 78.6% | $-1,175,318,000 | -1917.9% |
| 2021 | $55.3M | +132.3% | $46.3M | 83.8% | $-1,351,642,000 | -2444.8% |
| 2020 | $23.8M | -64.8% | $21.7M | 91.4% | $-1,070,898,000 | -4500.5% |
| 2019 | $67.7M | - | $66.6M | 98.3% | $-532,425,000 | -786.6% |
See ROIV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ROIV Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ROIV vs AGIO
See how ROIV stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ROIV's revenue growth accelerating or slowing?
ROIV revenue declined -77.8% year-over-year, contrasting with the 5-year CAGR of -15.6%. TTM revenue fell to $13M. This reverses the prior growth trend.
What is ROIV's long-term revenue growth rate?
Roivant Sciences Ltd.'s 5-year revenue CAGR of -15.6% reflects the variable expansion pattern. Current YoY growth of -77.8% is below this long-term average.
How is ROIV's revenue distributed by segment?
ROIV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.